The Royal Preston Hospital or RPH, is an acute general hospital in Preston, Lancashire, England. It is managed by the Lancashire Teaching Hospitals NHS Foundation Trust.
Aim To determine whether perivascular botulinum toxin injections can improve the symptoms associated with post traumatic cold intolerance. Materials and methods Patients were referred by the hand trauma or hand therapy teams to a cold intolerance clinic if they reported symptoms. The patients were seen at an initial appointment, 3–4 weeks and 3 months post injection. Twenty-eight patients received perivascular injections, comprising 20 units to each affected artery. The McCabe Cold-Sensitivity Severity Scale (CSSS) were completed at each appointment. Parametric and non-parametric data were analyzed using the paired t-test and Wilcoxon signed rank test, respectively. Results Twenty-two patients were followed-up. There were statistically significant improvements in the patients’ CSSS scores (p = 0.0118) and perception of weakness of their injured hands at the 3–4 weeks follow-up (p = 0.0008). Overall, 81% of patients indicated that they would recommend the treatment to a friend with similar problems, the remaining 19% said they were unsure, and no patients reported that they would not recommend the treatment. Conclusions Perivascular botulinum injections can improve the symptoms associated with cold intolerance. Further research is needed to determine the timing and frequency of the injections.
473 Background: KEYNOTE-564 demonstrated that adjuvant pembrolizumab improves outcomes after nephrectomy for clear-cell renal cell carcinoma (RCC). Whether this benefit extends to non–clear cell RCC (nccRCC) remains uncertain. We evaluated the association between adjuvant pembrolizumab and outcomes in patients with nccRCC who underwent nephrectomy in a multicenter study. Methods: We conducted a retrospective multicenter cohort study at six international institutions. Eligible adults had nccRCC treated with nephrectomy and were classified by receipt of adjuvant pembrolizumab. The primary endpoints were disease-free survival (DFS), defined as the time from nephrectomy to the first radiographic or clinical recurrence, and overall survival (OS), defined as the time from diagnosis to death or last follow-up. Survival functions were estimated with the Kaplan–Meier method and compared between groups using the log-rank test. Estimates of median DFS and OS were calculated using the Kaplan–Meier method. Results: Patient characteristics are shown in Table 1. Among 90 patients, 15 (17%) received adjuvant pembrolizumab, and 75 (83%) were observed; age at diagnosis was 56.0 years (IQR 44.0–63.0; mean 52.9 ± 13.1) and 62.0 years (IQR 52.0–71.0; mean 59.6 ± 14.7) respectively. Recurrence occurred in 7/15 (46.7%) with pembrolizumab and 25/75 (44.6%) with observation. There was no significant difference in median DFS (p = 0.75) or OS (p = 0.89) between groups. Median DFS was 90.7 months (95% CI, 27.2–NR) with pembrolizumab vs 41.9 months (95% CI, 39.4–NR) with observation; median OS was not reached (95% CI, 65.1–NR) with pembrolizumab vs 52.4 months (95% CI, 44.4–NR) with observation. Conclusions: In this descriptive retrospective six-center cohort of nccRCC post-nephrectomy, adjuvant pembrolizumab did not demonstrate a DFS or OS advantage over observation. A larger multi-institutional cohort is in progress to refine effect estimates using richer clinical detail, with adjusted analyses and prespecified subgroup assessment. Baseline characteristics by treatment group. Characteristic Overall (n=90) Observation (n=75) Pembrolizumab (n=15) Sex (Male/Female), n (ratio) 58 / 32 (1.8:1) 48 / 27 (1.8:1) 10 / 5 (2:1) T1, n (%) 11 (12.2%) 10 (13.3%) 1 (6.7%) T2, n (%) 10 (11.1%) 10 (13.3%) 0 (0.0%) T3, n (%) 64 (71.1%) 52 (69.3%) 12 (80.0%) T4, n (%) 3 (3.3%) 2 (2.7%) 1 (6.7%) Papillary RCC, n (%) 41 (45.6%) 36 (48.0%) 5 (33.3%) Chromophobe RCC, n (%) 31 (34.4%) 27 (36.0%) 4 (26.7%) Unclassified RCC, n (%) 7 (7.8%) 6 (8.0%) 1 (6.7%) Xp11 translocation, n (%) 8 (8.9%) 4 (5.3%) 4 (26.7%)
INTRODUCTION: In this manuscript, we evaluated the clinicopathological features of low-grade appendiceal mucinous neoplasm (LAMN), a unique type of appendiceal tumors. METHODS: This is a retrospective study that included patients with LAMN who were presented to our center from January 2008 to December 2024. The epidemiological, clinical, pathological, therapeutic, and prognostic data were analyzed. RESULTS: A total of 68 patients were included in the study, with a median age of 55.8 years. Forty patients (58.8%) had pseudomyxoma peritonei (PMP) at the time of diagnosis. Surgical cytoreduction was used in 44 patients (65.7%), while appendectomy was performed in 23 patients (34.3%). HIPEC was used only in fifteen patients (22.4%). Gross perforation was identified in 7 cases (10.3%). While microscopically, micro-perforation or rupture was noted in 20 patients (29.4%). Adjuvant systemic treatment was used in 50% of the patients. Over a median follow-up of 18 months, recurrence occurred in 21 patients (31.8%), while five patients (7.4%) developed distant metastasis. Mortality rate was 20.5% (n=14), including five patients who died postoperatively, while nine showed tumor-related mortality. On univariate analysis, only adjuvant treatments showed statistically significant correlation with the incidence of recurrence (p=0.007). CONCLUSIONS: The higher recurrence and mortality rates observed in our cohort compared with recent literature reflect the advanced disease burden and lower utilization of HIPEC. Future work should aim to refine patient selection for HIPEC, standardize operative approaches to minimize recurrence risk, and explore the role of adjuvant systemic therapy in reducing disease progression.